Physician profile
Christopher Lemmon
NPI 1679955579
$518.38
in general payments reported to CMS, 2019-2025
11 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2021: $79.99 · 2023: $37.82 · 2024: $121 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247 · Education: $16.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.83 |
| Education | $16.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $155.98 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $103.82 | 2024-2025 | |
| Janssen Biotech, INC. | $99.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $61.97 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $55.81 | 2023-2025 | |
| Tersera Therapeutics LLC | $25.23 | 2024 | Zoladex |
| E.R. Squibb & Sons, L.L.C. | $16.57 | 2023 | Opdivo |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lemmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.